Navigation Links
Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes

ed in patients with moderate and severe renal insufficiency, as well as in ESRD patients requiring hemodialysis. (See Dosage and Administration (2.2).) Hepatic Insufficiency In patients with moderate hepatic insufficiency (Child-Pugh score 7 to 9), mean AUC and Cmax of sitagliptin increased approximately 21% and 13%, respectively, compared to healthy matched controls following administration of a single 100 mg dose of JANUVIA. These differences are not considered to be clinically meaningful. No dosage adjustment for JANUVIA is necessary for patients with mild or moderate hepatic insufficiency. There is no clinical experience in patients with severe hepatic insufficiency (Child-Pugh score greater than9). Body Mass Index (BMI) No dosage adjustment is necessary based on BMI. Body mass index had no clinically meaningful effect on the pharmacokinetics of sitagliptin based on a composite analysis of Phase I pharmacokinetic data and on a population pharmacokinetic analysis of Phase I and Phase II data. Gender No dosage adjustment is necessary based on gender. Gender had no clinically meaningful effect on the pharmacokinetics of sitagliptin based on a composite analysis of Phase I pharmacokinetic data and on a population pharmacokinetic analysis of Phase I and Phase II data. Geriatric No dosage adjustment is required based solely on age. When the effects of age on renal function are taken into account, age alone did not have a clinically meaningful impact on the pharmacokinetics of sitagliptin based on a population pharmacokinetic analysis. Elderly subjects (65 to 80 years) had approximately 19% higher plasma concentrations of sitagliptin compared to younger subjects. Pediatric Studies characterizing the pharmacokinetics of sitagliptin in pediatric patients have not been performed. Race No dosage adjustment is necessary based on race. Race had no clinically meaningful effec
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
2. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
3. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
4. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
5. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
6. Everest Data on Short- and Long-Term Use of Otsukas Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACCs Late Breaking Clinical Trials
7. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
8. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
9. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
10. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
Post Your Comments:
(Date:8/22/2014)... , Aug. 22, 2014 /CNW/ - On Aug. 20, ... , the Canadian Medical Association (CMA) voted on and ... plant material, including medicinal cannabis. Bedrocan Cannabis Corp., a ... of the CMA motion. The CMA is ... hazards associated with smoking any plant material, including medicinal ...
(Date:8/22/2014)... COLUMBUS, Ohio , Aug. 22, 2014 MC ... Devices Inc. (MID), a Columbus, OH ... to distribute the FloShield laparoscopic and robotic visualization system in ... will be approved for sale in Japan ... has a long-time experience and an extensive product portfolio in ...
(Date:8/22/2014)... Research and Markets has announced ... Respirators Industry Report 2014" report to their offering. ... Industry Report 2014 is a professional and in-depth study ... industry with a focus on the Chinese situation. ... including definitions, classifications, applications and industry chain structure. The ...
Breaking Medicine Technology:Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2MC Medical agrees to be the exclusive distributor of FloShield products in Japan 2Global and Chinese Particulate Respirators Industry Report 2014 2
... 2011 Quest Diagnostics Incorporated (NYSE: DGX ... and services, announced that it is scheduled to speak ... York City. The presentation is scheduled for Tuesday, September ... The presentation will be webcast live during the conference ...
... Sept. 8, 2011 Spherix Incorporated ... in biotechnology for therapy in diabetes, metabolic syndrome ... consulting services to food, supplement, biotechnology and pharmaceutical ... SPX-106, achieved statistically significant reductions in VLDL and ...
Cached Medicine Technology:SPX-106T Treatment Yields Significant Reductions in Serum VLDL and LDL Cholesterol in Mice 2SPX-106T Treatment Yields Significant Reductions in Serum VLDL and LDL Cholesterol in Mice 3
(Date:8/23/2014)... August 23, 2014 On Monday, August ... a data breach suffered by Community Health Systems, ... compromise of 4.5 million records containing Personally Identifiable Information ... According to Mandiant, who was engaged to investigate the ... an advanced group of cyber attackers based in China, ...
(Date:8/23/2014)... 2014 Pixel Film Studios, a leader of ... release of ProIntro Vol.3, a customizable title tool for ... tile just by dragging ProIntro Vol.3 in their timeline" says ... a definite time saver and i think our users will ... beautifully designed titles made with Final Cut Pro X users ...
(Date:8/23/2014)... (PRWEB) August 23, 2014 Teen drug ... Carolina. It’s no different in Wilmington, NC. Substance abuse ... are falling victim to drug and alcohol dependency in ... are looking to overcome substance abuse, but don’t know ... adolescent treatment facility can be a challenge because most ...
(Date:8/22/2014)... The IT manager of Top10BestSEOHosting.com is ... several years. He has recently announced that GoDaddy ( ... in 2014. , GoDaddy is a popular supplier of ... great hosting solutions at affordable rates. It offers three ... hosting plans depend on the length of the contract. ...
(Date:8/22/2014)... Today, Zane Benefits, the #1 Online ... Health Plans. , According to Zane Benefits, employers are ... lower the cost of healthcare without reducing coverage for ... however, can be confusing. , The new guide contains ... main types of ABHPs. It also explains the ...
Breaking Medicine News(10 mins):Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 2Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 3Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 4Health News:A new plugin was announced today, ProIntro Vol.3 from Pixel Film Studios for Final Cut Pro X 2Health News:Troubled Teens Wilmington Helpline Guides Adolescents to the Path of Recovery 2
... News) -- The prevalence of psoriasis -- a chronic, inflammatory ... and obese kids, researchers have found. The Kaiser ... , also found that teens with psoriasis (regardless of their ... risk for heart disease. "This study suggests a ...
... 20 (HealthDay News) -- For the average listener, the ... speaker,s sexual orientation, a new study finds. "I,m not ... vowel," study lead author Erik C. Tracy, a cognitive psychologist ... the American Institute of Physics. "Other researchers have done various ...
... , FRIDAY, May 20 (HealthDay News) -- All ... to 11 years old, according to new guidelines from the ... with a family history of premature cardiovascular disease or elevated ... as early as age 2. "It,s important that people ...
... Dr. Jeffrey M. Trent, F.A.C.M.G., a nationally recognized ... has been appointed Foreign Trade Counselor of Luxembourg in ... and Research Director of the Translational Genomics Research Institute ... Grand Rapids, Michigan. Both non-profit biomedical research institutes study ...
... News) -- Though a new study suggests that a dietary ... develop preeclampsia, the jury is still out over whether it ... it yet. Preeclampsia is a pregnancy complication ... hypertension. It affects about 5 percent of first pregnancies. ...
... SESSION I / Monday, May 23 / 8 ... Acute Coronary Syndrome Patients in Real World Clinical Practice: Observations ... Bhandary D2, Stephenson JJ1, Gold A2, Fu AC1, Kern DM1, ... SESSION II / Tuesday, May 24 / 8 ...
Cached Medicine News:Health News:Study Sees Link Between Psoriasis, Obesity in Kids 2Health News:Straight or Gay? Vowels in Speech May Give it Away 2Health News:Experts Say Cholesterol Screenings Should Start in Childhood 2Health News:TGen/VARI president Dr. Jeffrey Trent appointed Foreign Trade Counselor by Luxembourg 2Health News:Study Suggests Supplement May Protect Against Preeclampsia 2Health News:HealthCore presents ISPOR poster sessions 2
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Medicine Products: